ClinicalTrials.gov
ClinicalTrials.gov Menu

Letrozole Versus Clomifene Citrate for Ovulation Induction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00478504
Recruitment Status : Completed
First Posted : May 24, 2007
Last Update Posted : October 28, 2016
Sponsor:
Collaborator:
Derby Hospitals NHS Foundation Trust
Information provided by (Responsible Party):
Saad Amer, University of Nottingham

Brief Summary:
The primary aim of the study is to assess the efficacy of letrozole as an ovulation induction agent and to test the hypothesis that letrozole will generate better pregnancy rates with fewer multiple pregnancies and higher live birth rate than the current standard agent, clomifene citrate in anovular infertile women with polycystic ovarian syndrome.

Condition or disease Intervention/treatment Phase
Infertility Polycystic Ovarian Syndrome Drug: Letrozole Drug: Clomifene citrate Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 159 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double Blind Cross-over Randomized Controlled Trial Comparing Letrozole Versus Clomifene Citrate for Ovulation Induction in Women With Polycystic Ovarian Syndrome
Study Start Date : May 2007
Actual Primary Completion Date : June 2014
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Clomiphene citrate
Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
Drug: Clomifene citrate
Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg

Active Comparator: Letrozole
Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg
Drug: Letrozole
Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg




Primary Outcome Measures :
  1. Pregnancy rate [ Time Frame: 14 moths ]

Secondary Outcome Measures :
  1. 1. Ovulation rate 2. Number of growing and mature follicles during treatment 3. Miscarriage rate 4. Live-birth rate 5. Multiple pregnancy rate 6. Endometrial thickness [ Time Frame: 14 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 39 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age: 18 - 39
  2. BMI < 36
  3. Infertility due to anovulation
  4. PCOS: At least two of the following diagnostic criteria of:

    1. Oligo/amenorrhoea
    2. Hyperandrogenaemia: biochemical (testosterone ≥2.5 nmol/l or free androgen index (FAI) ≥ 5) or clinical (acne/hirsutism) evidence
    3. USS evidence of PCO (either ≥12 follicles measuring 2-9 mm in diameter, or an ovarian volume of > 10 ml)
  5. No recent (within 6 months) treatment for induction of ovulation
  6. Normal semen analysis (WHO 1999)
  7. Proven patency of at least one Fallopian tube

Exclusion Criteria:

  1. Inability to give informed consent
  2. Contraindication to letrozole or clomifene citrate
  3. Absence of any inclusion criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00478504


Locations
United Kingdom
Royal Derby Hospital
Derby, Derbyshire, United Kingdom, DE22 3NE
Sponsors and Collaborators
University of Nottingham
Derby Hospitals NHS Foundation Trust
Investigators
Principal Investigator: Saad Amer, MD, MRCOG University of Nottingham and Derby Hospitals NHS foundation Trust

Additional Information:
Responsible Party: Saad Amer, Associate Professor, University of Nottingham
ClinicalTrials.gov Identifier: NCT00478504     History of Changes
Other Study ID Numbers: RD-5103-015-06
EudraCT No: 2006-006514-15
First Posted: May 24, 2007    Key Record Dates
Last Update Posted: October 28, 2016
Last Verified: October 2016

Keywords provided by Saad Amer, University of Nottingham:
anovulation
ovulation induction,
polycystic ovarian syndrome
clomifene citrate
letrozole

Additional relevant MeSH terms:
Syndrome
Infertility
Polycystic Ovary Syndrome
Disease
Pathologic Processes
Genital Diseases, Male
Genital Diseases, Female
Ovarian Cysts
Cysts
Neoplasms
Ovarian Diseases
Adnexal Diseases
Gonadal Disorders
Endocrine System Diseases
Citric Acid
Letrozole
Clomiphene
Enclomiphene
Zuclomiphene
Anticoagulants
Calcium Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Estrogen Antagonists
Hormone Antagonists